- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01590238
Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)
December 29, 2016 updated by: Anthony P. Sclafani, The New York Eye & Ear Infirmary
Clinical alopecia occurs due to miniaturization of the hair shafts as well as loss of active production of hair shafts.
PRFM has been shown to induce dermal angiogenesis, and anecdotal findings of improvement of hair appearance after PRFM injection in the scalp suggest that PRFM may play a role in the treatment of thinning hair.
Patients will be treated on a monthly basis with intradermal injections of autologous PRFM for 3 months.
Changes in hair density will be assessed by comparing pre- and post-treatment photographs and non-invasive measurements of hair density at 1, 2, 3, 4 and 6 months after initial treatment.
Study Overview
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
New York, New York, United States, 10003
- The New York Eye & Ear Infirmary
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years to 71 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- age 18- 75 years old
- frontal and/or crown alopecia
Exclusion Criteria:
- bleeding disorder
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Treatment with PRFM
Subjects treated monthly 3 times with intradermal injections of PRFM into bald/balding scalp.
Post-treatment hair density index measured and compared to hair density index measured prior to treatment for each subject.
|
Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit.
4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood.
PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hair Density Change After Three Treatments
Time Frame: 6 months after initial visit
|
Hair density index at calibrated distance from glabella in a 2 cm x 2 cm midline square at 6 month follow up visit as a percentage of initial (pre-treatment) hair density index, measured using a proprietary hair densitometer.
|
6 months after initial visit
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Actual)
September 1, 2013
Study Completion (Actual)
November 1, 2013
Study Registration Dates
First Submitted
April 29, 2012
First Submitted That Met QC Criteria
May 1, 2012
First Posted (Estimate)
May 2, 2012
Study Record Updates
Last Update Posted (Actual)
February 15, 2017
Last Update Submitted That Met QC Criteria
December 29, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2012-1 (SUNY Upstate IRB (Upstate Medical University))
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alopecia
-
Erasmus Medical CenterRecruitingAlopecia Areata(AA) | Alopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU) | Alopecia Totalis/Universalis | Alopecia Areata (& Ophiasis)Netherlands
-
Hayat Abad Medical Complex, PeshawarNot yet recruitingAlopecia Areata | Alopecia Universalis | Alopecia Totalis (AT)
-
Siriraj HospitalCompletedRecalcitrant Alopecia Totalis | Recalcitrant Alopecia UniversalisThailand
-
Yale UniversityCompletedFibrosing Alopecia | Frontal Fibrosing Alopecia | Central Centrifugal Cicatricial AlopeciaUnited States
-
Aclaris Therapeutics, Inc.CompletedAlopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Yale UniversityCompletedAlopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)United States
-
Hayat Abad Medical Complex, PeshawarNot yet recruiting
-
University of MinnesotaColumbia UniversityRecruitingAlopecia Areata | Alopecia Totalis | Alopecia UniversalisUnited States
-
NanoAlvandCompletedAlopecia Areata(AA) | Alopecia Totalis/UniversalisIran, Islamic Republic of
-
PfizerRecruitingSevere Alopecia AreataSouth Korea
Clinical Trials on PRFM treatment
-
HealthPartners InstituteMusculoskeletal Transplant FoundationCompleted
-
KLE Society's Institute of Dental SciencesUnknown
-
New York Medical CollegeCompletedWrinkle | Nasolabial Fold | Skin Rejuvenation | Skin QualityUnited States
-
Fraser Orthopaedic Research SocietyWithdrawn
-
KLE Society's Institute of Dental SciencesUnknownIntrabony Periodontal DefectIndia
-
PfizerCompleted
-
Chiesi Farmaceutici S.p.A.Completed
-
PfizerCompleted
-
Gilead SciencesCompletedChronic Lymphocytic LeukemiaUnited States
-
JW PharmaceuticalCompletedHealthyKorea, Republic of